Novartis Announces Completion of Acquisition of Tourmaline Bio, Inc.

Source: PR Newswire

Shanghai, November 12, 2025 /PR Newswire/ -- Recently, Novartis announced the successful completion of its acquisition of Tourmaline Bio, Inc. ("Tourmaline"). With the completion of the acquisition, Tourmaline's common stock (par value of $0.0001 per share, hereinafter referred to as "shares") has ceased trading on The Nasdaq Stock Market LLC, and Tourmaline is now an indirect wholly-owned subsidiary of Novartis.

"The acquisition of Tourmaline Bio is highly aligned with our strategy to deepen our expertise in areas where Novartis can lead and truly create value for cardiovascular innovation," said Shreeram Aradhye, President of Global Drug Development and Chief Medical Officer at Novartis. "Pacibekitug*, with its unique mechanism of targeting IL-6, offers a compelling and evidence-based new approach to addressing residual inflammation, a key driver of atherosclerotic cardiovascular disease. We look forward to collaborating with the Tourmaline team to accelerate the development of this highly promising asset and further strengthen our ability to deliver potentially transformative therapies in areas of high unmet medical need."

* Pacibekitug is an anti-IL-6 monoclonal antibody that holds promise as a potential treatment for residual inflammatory risk in ASCVD.

About Novartis

Novartis is an innovative pharmaceutical company. We constantly strive to envision the future of medicine, improve people's quality of life, and extend human lifespan, thereby empowering patients, healthcare professionals, and society when facing serious disease challenges. In 2024, our medicines will benefit nearly 300 million people worldwide.

About Novartis in China

Novartis is an innovative pharmaceutical company, with its Chinese name signifying "a promise to China," meaning improving the health and quality of life of the Chinese people through continuously innovative products and services. Since 1987, Novartis has had over 100 innovative drugs and new indications approved in China.